Introduction {#s1}
============

Human lymphoma cell lines and animal models have contributed significantly to better understand the physiopathology of hematopoietic tumors. Cell lines are generally characterized by monoclonal origin, differentiation arrest and sustained proliferation *in vitro*, while maintaining most cellular features and specific genetic alterations of the primitive tumor [@pone.0052811-Drexler1]. However, primitive malignant cells may change some morphological and phenotypic features in culture, due to Epstein-Barr virus (EBV) infection. EBV is a B lymphotropic herpesvirus linked to several B cell malignancies and capable of transforming human B cell into permanent lymphoblastoid cell line *in vitro* [@pone.0052811-Altmann1]. Besides Hodgkin lymphoma, Burkitt lymphoma, human immunodeficiency virus-associated lymphomas and post-transplant lymphoproliferative disorders [@pone.0052811-Chen1], EBV has been also detected in low-grade lymphoproliferative diseases such as chronic lymphocytic leukemia (CLL) where it has been shown to correlate with transformation to Richter syndrome in some cases [@pone.0052811-Tarrand1], [@pone.0052811-Rossi1], [@pone.0052811-Ansell1].

Many types of small B lymphoid neoplasms can demonstrate plasmacytic differentiation and specific immunophenotypic or genetic markers for plasmacytic lymphoma; furthermore, small B-cell lymphomas with plasmacytic differentiation frequently represent a diagnostic challenge, and sometimes only a diagnosis of small B-cell lymphoma with plasmacytic differentiation can be done [@pone.0052811-Campo1]. All of these disorders may potentially undergo transformation to large-cell lymphoma [@pone.0052811-Pangalis1].

Diffuse large B-cell lymphoma (DLBCL) represents a very heterogeneous group of aggressive lymphomas. Following the introduction of gene expression profiling (GEP), it has become increasingly clear that DLBCL is a biologically and clinically heterogeneous disorder. Two major categories are now recognized, i.e. germinal center B-cell (GCB) and activated B-cell (ABC) types, which are different for the expression of more than 1000 genes. In the attempt at traslating GEP classification into daily practice, several immunohistochemical algorithms have been proposed as a surrogate for GEP analysis [@pone.0052811-Choi1].

Some aggressive DLBCL show the phenotype of terminal B-cell differentiation and represent a continuum spectrum of lesions that ranges from conventional activated DLBCL to plasma cell disorders with specific molecular patterns [@pone.0052811-MontesMoreno1], some of which, including Myd88, have been recently suggested to correlate with plasmacytic lymphoma histotype [@pone.0052811-Puente1], [@pone.0052811-Ngo1].

We describe here the established VR09 cell line, an EBV-positive cell line with plasmacytic differentiation displaying tumorigenic potential *in vivo* and leading to the development of activated DLBCL with plasmacytic features when injected into Rag2^−/−^ γ-chain^−/−^ mice. Thus, VR09 xenotrasplantation can be used successfully as preclinical model for human DLBCL with plasmacytic differentiation to further characterize this disease.

Materials and Methods {#s2}
=====================

Cell Collection and Culture {#s2a}
---------------------------

A 75-year old Caucasian man was admitted to hospital in September 2008 for fever, neutropenia and lymphocytosis (WBC 20.1×10^9^/L, with neutrophils 0.8×10^9^/L and lymphocytes 18.2×10^9^/L), and moderate anemia and trombocytopenia (Hb 9 g/dl, PLTS 93×10^9^/L). No significant superficial lymphoadenopathy or splenomegaly were present. Peripheral blood smear shows the predominance of small-medium sized mature lymphoid cells with abundant cytoplasm and compact chromatin **(** [**Figure 1A**](#pone-0052811-g001){ref-type="fig"} **)**. A bone marrow sample was sent to our laboratory for first level-immunophenotyping by flow cytometry (FACSCanto, Becton Dickinson Biosciences, CA, USA), after written informed consent, as approved by the Ethics Committee of Azienda Ospedaliera Universitaria Integrata Verona (N. Prog. 1828, May 12, 2010 - 'Institution of cell and tissue collection for biomedical research in Onco-Hematology'). Bone marrow smear appeared infiltrated (60%) by a cell population of lymphoplasmocytoid elements of small-medium size ([**Figure 1B**](#pone-0052811-g001){ref-type="fig"}). First level-immunophenotyping showed the presence of a cell population expressing CD19, CD20, CD22, CD138, surface immunoglobulins (sIg) at high level, and negative for CD5, CD10, ZAP-70, thus suggesting the diagnosis of non-CLL atypical B-cell chronic lymphoproliferative disease with plasmacytic features. No other exams could be performed, as the patient died of sepsis the following day.

![Morphology of primary malignant cells and VR09 cell line.\
Morphological features of patient's primary cells and VR09 cells in suspension, as assessed by May-Grünwald-Giemsa staining. (A) Patient's peripheral blood cells. (B) Patient's bone marrow cells. (C) VR09 cells: small and round clumps in suspension. (D) VR09 cells: plasmacytoid appearance, with irregular nucleus, compact chromatin and abundant basophilic cytoplasm.](pone.0052811.g001){#pone-0052811-g001}

Mononuclear cells were purified from bone marrow sample by Ficoll-Paque centrifugation (Lymphoprep, Fresenius Kabi Norge AS for Axis-Shield Poc AS, Oslo, Norway), washed in phosphate-buffered saline solution (PBS) and resuspended at 1×10^6^/mL concentration in RPMI 1640+ GlutaMAX 1X containing 10% heat-inactivated fetal bovine serum and 1% penicillin/streptomycin (all from GIBCO, Invitrogen). Cells were cultured in 75 cm^2^ flask and incubated in humidified 5% CO~2~ atmosphere at 37°C. Half of culture medium was replaced every 3--4 days maintaining the same cell density of 1×10^6^ cells/mL. To determine growth kinetics, cells were seeded at lower density (350,000/mL) and counted at 0, 24, 48 and 72 hours by flow-cytometry (FACSCanto, Becton Dickinson, Italy). No mitogens or growth factors were added during culture. Cells were maintained in culture up to one year. Cell morphology was evaluated on cytospins stained with May-Grunwald Giemsa dye.

Immunophenotypic Analysis {#s2b}
-------------------------

Cell vitality was assessed by acridine-orange/ethidium bromide staining and epifluorescent microscopy. Aliquots of 3×10^5^ cells were incubated for 15 minutes at room temperature with three-color combinations of appropriate monoclonal antibodies anti-human CD3, CD19, CD20, CD22, CD23, CD25, CD38, CD43, CD45, FMC-7, CD79b 7AAD (Becton Dickinson, Italy), CD5, CD10, K, λ, IgG, IgM, IgD (Dako, Italy), CD103 (Beckman Coulter, Italy), CD138 (Cytognos, Italy), and isotype controls (Becton Dickinson, Italy). Samples were analyzed by FacsCANTO flow cytometer with BD FACSDiva software (Becton Dickinson, Italy).

Cell Cycle {#s2c}
----------

For determination of the DNA content, 1.5×10^5^ cells were incubated with 1 ml of staining solution including 5 ml of hypotonic solution, 50 µg of propidium iodide (Bender MedSystems) and 20 µg of RNAse for two hours at 4°C analyzed using appropriate settings by FacsCanto flow cytometer. Human peripheral mononuclear cells were used as control for the comparison of S fraction.

DNA and RNA Extraction, cDNA Synthesis {#s2d}
--------------------------------------

DNA and RNA were obtained from 10^7^ cells by AllPrep DNA/RNA/Protein Mini Kit (Quiagen, Hilden, Germany). DNA quality was verified by spectrophotometry and RNA quality by the Agilent Bionanalyzer 2100; 1 µg of total RNA was reverse-transcribed by using SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad, California) and cDNA was used as a template for reverse transcriptase polymerase chain reaction (RT-PCR) amplification using listed in [**Table 1**](#pone-0052811-t001){ref-type="table"}.

10.1371/journal.pone.0052811.t001

###### Primers used to amplify and sequence P53, Card 11, CD79B, MYD88 AND RPMS1 genes.

![](pone.0052811.t001){#pone-0052811-t001-1}

  Primers                  Sequence              Ta°    Amplicon lenght
  ------------ -------------------------------- ------ -----------------
  P53-1-F            AAGTCTAGAGCCACCGTCCA        55°C       771 bp
  P53-1-R         AAGTGTTTCTGTCATCCAAATACTC            
  P53-2-F            AGCCAAGTCTGTGACTTGCA        55°C       851 bp
  P53-2-R            GGGGAACAAGAAGTGGAGAA              
  Card11-1-F         AGATGCAACGGGAGCCTGGC        55°C       631 pb
  Card11-1-R         AGGTTAGCAGCTCCACGCGC              
  Card11-2-F         GGCCAAGGACCTGCAACGCT        55°C       703 pb
  Card11-2-R         CCGCTCCACCTCCTCCAGCT              
  Card11-3-F         GAGGCCCTGGAGGACAGGCA        55°C       690 pb
  Card11-3-R         TCCGCAGGAGCTAGGGCTGG              
  Card11-4-F         TCCTGCCCTACCATCCGCCC        55°C       671 pb
  Card11-4-R         CAGCAGCTGGTGGCCCTCAC              
  Card11-5-F         TCCCAGCTCACCCTGCTGGG        55°C       739 pb
  Card11-5-R         CCGAGATGATGCGGACCCGC              
  Card11-6-F         CCCGTCTCTCGCGAGCAAGC        55°C       928 pb
  Card11-6-R         CGTCTGCTGGGGCAGCTCTG              
  CD79B-1-F          GCCTCGGACGTTGTCACGGG        55°C      858 pb\*
  CD79B-1-R          TGGGCCAGCTTCAGAGGCCA              
  MYD88-EX1F         CGCAGGAGAAAGAGGAAGC         60°C       491 bp
  MYD88-EX1R         ATGGGAGACAGGATGCTGAG              
  MYD88-EX3F      TGGGTAAAGAGGTAGGCACTCCCAG      60°C       275 bp
  MYD88-EX2R      GCCCATCTGCTTCAAACACCCATGC            
  MYD88-EX3F      AAGCCTTCCCATGGAGCTCTGACCAC     60°C       311 bp
  MYD88-EX3R      GCTAGGAGGAGATGCCCAGTATCTG            
  MYD88-EX3F      ACTAAGTTGCCACAGGACCTGCAGC      60°C       194 bp
  MYD88-EX3R      ATCCAGAGGCCCCACCTACACATTC            
  MYD88-EX3F        GTTGTTAACCCTGGGGTTGAAG       60°C       297 bp
  MYD88-EX3R    GCAGAAGTACATGGACAGGCAGACAGATAC         
  RPMS1F             GGATGGGAGAGGGTGATCTT        60°C       151 bp
  RPMS1R             ACGTGGAGTTTGCAGTCCTC              

Isoform 1: 858 pb; Isoform 2: 546 pb; Isoform 3: 861 pb.

Analysis of VH Rearrangement, p53, CD79B, Card 11 and MYD88 Mutation {#s2e}
--------------------------------------------------------------------

To verify the identity between cells from the patient and the cell line, rearranged *VH* genes were analyzed as previously described [@pone.0052811-Zam1] in frozen DNA from both the patient and the cell line *TP53, CD79B* and *CARD11* genes were amplified and sequenced by using the primers reported in [**Table 1**](#pone-0052811-t001){ref-type="table"}. *MYD88* exons 1 to 5 were sequenced as previously described [@pone.0052811-Puente1], [@pone.0052811-Ngo1]. VH and CD79B PCR bands were excised from agarose gels and purified by using spin columns (PureLink Quick Gel Extraction and PCR Purification Combo Kit, Invitrogen). PCR products were sequenced by dye terminator reaction (Big Dye Terminator Cycle Sequencing Kit v.3.1, Applied Biosystems, Warrington, UK) on AB3130XL automated sequencer (Applied Biosystems). *TP53*, *CARD11* and *MYD88* PCR products were directly purified with magnetic beads (Agencourt AMPure XP, Beckman Coulter Genomics, Beverly, Massachussets, USA) and sequenced as reported above and by outsourcing to Base Clear BV (Leiden, The Netherlands).

VH genes sequences were compared to published germline sequences using IgBLAST (<http://www.ncbi.nlm.nih.gov/igblast/>). Sequences with 2% or less deviation from any germline IgVH sequence were considered unmutated. *TP53, CD79B*, *CARD11* and *MYD88* amplified sequences were compared to reference sequences by using Geneious software (Biomatters Ltd., Auckland, New Zealand).

Preparation of Formalin-fixed Paraffin-embedded (FFPE) Cell Block and Immunohistochemical Staining {#s2f}
--------------------------------------------------------------------------------------------------

Briefly, 12×10^6^ cells were centrifuged, washed once in PBS and then incubated for 15 minutes in 4% buffered formalin. Cells were centrifuged again and resuspended in 1 ml of 1% low melting point agarose at 37°C; then, they were poured into disposable plastic moulds and cooled for ten minutes at +4°C. Solid agarose blocks were put inside a histological cassette, with 4% buffered formalin at room temperature, and then processed routinely as tissue block; 4 µm-thick sections were cut from the block and stained with ematoxilin-eosin to verify the quality of the cell inclusion. Many sections from the block were immunolabeled with the broad panel of antibodies described in [**Table 2**](#pone-0052811-t002){ref-type="table"}. A 25% cut-off was used to distinguish positive from negative. All samples were processed by using a sensitive 'Bond polymer Refine' detection system in automated Bond immunostainer (BondMax, Vision-Biosystem, Menarini, Florence, Italy).

10.1371/journal.pone.0052811.t002

###### Marker expression by VR09 cell line and tumor masses, as assessed by immunohistochemistry performed on FFPE cell block.

![](pone.0052811.t002){#pone-0052811-t002-2}

  Antibody              Species      Clone              Source                Diluition         VR09 cell line   Tumor masses
  -------------------- --------- -------------- ---------------------- ----------------------- ---------------- --------------
  Annexin a1             mouse        B01P              Abnova                   100                 neg             neg
  Bcl-2                  mouse        124                Dako                    40                  pos             pos
  Bcl-6                  mouse        LN22            Novocastra                 20                  neg             neg
  Cyclin D1             rabbit        SP4             Neomarkers                 10                  neg             neg
  CD03                  rabbit        SP7             Labvision                  150                 neg             neg
  CD05                   mouse        4C7             Novocastra                 200                 neg             neg
  CD10                   mouse        56C6            Novocastra                 50                  neg             neg
  CD19                   mouse      LE-CD19            Serotec                   200                 pos             pos
  CD20                   mouse        L26             Novocastra                 100                 pos             pos
  CD22                   mouse        FPC1            Novocastra                 20                  pos             pos
  CD23                   mouse        1B12            Novocastra                 100                 pos             pos
  CD25 IL2R              mouse        4C9             Novocastra                 100               pos/neg         pos/neg
  CD38                   mouse       38C03            Neomarkers                 50                  neg           pos/neg
  CD43 (T cell)          mouse        MT1             Novocastra                 30                  pos             pos
  CD79alfa               mouse       JCB117              Dako                    100                 pos             pos
  CD79beta               mouse        JS01            Novocastra                 50                pos/neg         pos/neg
  CD123                  mouse        7G3                 Bd                     100                 neg           pos/neg
  CD138 (syndecan-1)     mouse        BB4              Serotec                   50                pos/neg         pos/neg
  DBA44 hairy cell       mouse       DBA.44              Dako                    20                  neg             neg
  FOXP1                  mouse        JC12              Abcam                    500                 neg           pos/neg
  EBV (EBER)                      mRNA probe\*    Vision Byosistems                                  pos             pos
  GCET1                  mouse       RAM341             Abcam                    500                 neg             neg
  HHV-8                  mouse       13B10            Novocastra                 50                  neg             neg
  IgD                   rabbit     polyclonal            Dako                    20                  pos           pos/neg
  IgG                   rabbit     polyclonal            Dako                   10000                neg             neg
  IgM                   rabbit     polyclonal            Dako                   5000               pos/neg         pos/neg
  Ki-67                  mouse        MM1             Novocastra        20000(15′ incubation)      pos(40%)        pos(80%)
  ZAP-70                 mouse       2F3.2             Upstate                   200                 neg             neg
  κ chains              rabbit     polyclonal            Dako                    50                  pos             pos
  λ chains              rabbit                           Dako                   30000                neg             neg
  MNDA                   mouse        235        provided by CNIO\*\*             2                  pos             pos
  MUM1 Protein           mouse       MUM1p               Dako                    50                  pos             pos
  PAX 5                  mouse        1EW             Novocastra                 50                pos/neg         pos/neg
  P53 Protein            mouse        DO-7            Novocastra                 20                pos/neg         pos/neg
  Sox11                 rabbit     polyclonal        Atlas Sigma                 50                pos/neg         pos/neg
  TCL1A                  mouse       1--21            Santa Cruz                 100               pos/neg         pos/neg
  TdT                   rabbit     polyclonal            Dako                    30                  neg             neg
  TRAcP                  mouse        26E5            Neomarkers                 30                  neg             neg

Establishment of the Mouse in vivo Model {#s2g}
----------------------------------------

Three month-old immunodeficient Rag2^−/−^ γ-chain^−/−^ mice (Taconic animal models, New York's River Valley, NY USA) were injected either subcutaneously (s.c.) (n = 6) with 5×10^6^ VR09 cells, resuspended in 0.2 ml PBS, or intravenously (i.v) (n = 6) with 0.5×10^6^ VR09 cells resuspended in 0.1 ml PBS. Animals were checked three times a week for the development of tumors. When s.c. tumors developed up to approximately 2 cm of diameter, corresponding to a spheric volume of approximately 4.187 cm^3^, mice were killed. Half of the tumor mass was frozen and half included in paraffin according to standard procedures. Sections of 5--8 µm from each tumoral mass were prepared and analyzed for morphology, immunohistochemistry and FISH. Paraffin sections for immunohistochemistry were stained with a panel of antibodies, as described above ([**Table 2**](#pone-0052811-t002){ref-type="table"}). Moreover, a little portion of the mass from two of six s.c injected mice, was dissected and mechanically dissociated into single-cell suspension; 1.5×10^6^ cells from each tumor were cultured in RPMI +10% FBS and incubated as described above. Immunophenotipic analysis was performed on secondary cell culture after two months of culture, as previously described.

Three of six mice injected i.v. were euthanized at +30 days, while the others were sacrificed after four months from the treatment. Spleen, liver, femurs, lymph nodes, lungs and bowel of the i.v. injected animals were collected and included in paraffine. Tissue sections were immunostained with antibodies against CD20 and CD138 to verify the presence on tumor infiltration. In addition, immunophenotyping with anti-human CD19 and CD45 monoclonal antibodies and isotype controls was performed by standard procedures on peripheral blood mononuclear cells of all mice injected both s.c. and i.v.

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The *in vivo* studies were approved by Verona University Ethical Committee for experimentation on animals (Prot. n°51 del 16/06/11, D.lgs 116/92).

EBV Status Evaluation {#s2h}
---------------------

The presence of EBV was assessed on both cells cultured *in vitro* and cells obtained from the tumoral mass developing after *in vivo* injection of VR09 cell line. Epstein-Barr virus-encoded RNA (EBER) hybridization was performed on cytoinclusion by means of specific fluorescein-conjugated EBER probes (Bond ISH EBER Probe, Vision-Biosystem, Menarini, Florence, Italy). EBER sequence was detected by anti-fluorescin antibody associated with a sensitive 'Bond polymer Refine' chromogenic detection system in an automated immunostainer (Bondmax, Vision-Biosystem, Menarini, Florence, Italy).

To verify that EBV infection of VR09 derived directly from the patient, the presence of EBV gene RPMS1 was detected by PCR amplification on both DNA from the patient and VR09 cell line. The reaction was performed in a final volume of 50 ml, containing 5 ml Taq Buffer Advanced (5 Prime, Hamburg, Germany), 5 pmol of each primer (listed in [Table 1](#pone-0052811-t001){ref-type="table"}), 200 mM each dNTP and 1.25 U of Taq DNA Polymerase (5 Prime). Cycling conditions were 2 minutes at 94°C, 20 seconds at 60°C, 40 seconds at 68°C, then a final elongation of 5 minutes at 68°C. PCR products were analyzed on a 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany), using the Agilent DNA1000 chip and reagents. Electronic data were analyzed using the manufacturer's software (Agilent 2100 Expert).

Karyotyping and Fluorescence in situ Hybridization (FISH) {#s2i}
---------------------------------------------------------

Cytogenetic analysis was performed with standard methods on both cells cultured *in vitro* and cell suspensions from tumors developing after *in vivo* injection of VR09 cell line: 10--20×10^6^ cells were centrifuged, resuspended in RPMI 1640 medium containing 20% fetal bovine serum (FBS, Lonza, Verviers, Belgium) and cultured for 24 hours. Before harvest, 0.15 µg/ml colchicin (Eur-Clone, Italy) was added. Chromosome preparation and staining using QFQ technique was performed according to standard protocols. Karyotypes were scored according to the International System for Human Cytogenetic Nomenclature (ISCN) [@pone.0052811-Brothman1]. Images were captured with a ZEISS Axioplan microscope (ZEISS, Jena, Germany) and evaluated by Cytovision applied imaging system (Molecular Devices, New Milton).

Interphase cytogenetic FISH was performed on nuclei from VR09 cell suspension and formalin-fixed and paraffin-embedded tissue sections from *in vivo* tumor masses developing after *in vivo* injection of VR09 cell line. The following kits were used: LSI BCL-2 dual color probes for 14q32;18q21 (Abbott-Vysis, Olympus), LSI CCND1 (11q13) break-apart probes (Abbott-Vysis, Olympus), LSI IGH/CCND1 probe for 11q13-14q32.3 (Abbott-Vysis, Olympus), LSI MYC dual color break-apart probe for 8q24 (Abbott-Vysis, Olympus), LSI C-MYC dual color probes for 8q24-14q32 (Abbott-Vysis, Olympus) and CEP (centromeric) mapping 12p11.1-q11.1 (Abbott-Vysis, Olympus). Chromosome 9 probes from human painting box kit (Spectral Imaging) were also used to identify whole chromosome 9 on metaphases of cell derived from *in vivo* tumor masses. The procedure was performed according to the methods described elsewhere [@pone.0052811-Brunelli1].

FISH slides were examined by using either Axioplan (Zeiss, Germany) or Olympus BX61 (Olympus, Hamburg, Germany) epifluorescent automated microscopes. The signals were recorded using a CCD camera (Axiocam HRm, Zeiss and Digital Camera Olympus), and score was assigned according to manufacturer's instructions, available in each commercial FISH kit.

Results {#s3}
=======

Establishment and Characterization of VR09 Cell Line {#s3a}
----------------------------------------------------

Primary cells proliferated very slowly during the first six weeks of culture, with a consequent decline in cell number. Remaining cells formed a few clusters of proliferation and started growing in suspension forming small round clumps ([**Figure 1C**](#pone-0052811-g001){ref-type="fig"}). At ten weeks of culture a stable proliferating cell line (designed VR09) was established, with a doubling time of approximately 84 hours. May-Grünwald-Giemsa staining showed a wide cellular size spectrum, from medium to large cells, with plasmacytoid features and occasional bizarre shapes: cells had a round-ovoid, often eccentric or moderately irregular nucleus, with compact chromatin and abundant basophilic cytoplasm ([**Figure 1D**](#pone-0052811-g001){ref-type="fig"}). At present, VR09 cells grow in suspension in RPMI 1640 medium supplemented with 10% heat-inactivated FBS without requiring any other supplements, and can be vitally stored in a medium consisting of 60% RPMI 1640 medium, 30% heat-inactivated FBS and 10% DMSO. Once thawed and put in culture, VR09 cell line grows rapidly and maintains the same doubling time of the early culture. Cells are optimally maintained at 500,000 and 1,000,000/mL cell density and may be split 1∶5 every 72 hours.

Immunophenotype and Immunohistochemistry {#s3b}
----------------------------------------

Immunophenotyping by flow cytometry was performed on VR09 cell line at 10 weeks and one year after continuous culture, resembling the phenotype of atypical B-cell chronic lymphoproliferative disease with plasmacytic features found in the patient. In particular, cells were CD45^+^, CD19^+^, CD20^+^, CD22^+^, CD23^+^, CD43^+^, CD38^+^, CD138^+^, IgD^+^, IgM^+^, IgG^+^ and kappa chains^+^, and negative for CD3, CD5, CD10, CD25, CD79b, CD103, FMC7 and lambda chains ([**Figure 2**](#pone-0052811-g002){ref-type="fig"}); Zap-70, as expected, was not expressed. VR09 surface markers remained unchanged over time, with the exception of CD20, whose expression had a 1 log increase as compared to starting culture.

![Immunophenotype.\
Immunophenotyping of VR09 cell line (grey and filled curves) and cell suspensions from *in vivo* tumor mass (black and filled curves), as compared with isotype control (white curves).](pone.0052811.g002){#pone-0052811-g002}

Results of immunohistochemistry performed on FFPE cell block are summarized in [**Table 2**:](#pone-0052811-t002){ref-type="table"} all the markers shown by flow cytometry were confirmed, with the exception of IgG and CD38 expression that resulted negative by immunohistochemistry; proliferation index (Ki-67+ cells) was about 40%. In addition, cells were positive for Bcl-2, MNDA [@pone.0052811-Kanellis1] and MUM1, and negative for Bcl-6, Cyclin D1, Annexin A1, DBA44, GCET1, ZAP-70, TdT and TRAP; other markers, such as PAX-5, Sox11, FOXP1 and TCL1, were weakly and variably expressed. In summary, neoplastic cells displayed a late B-cell phenotype (MNDA+, FOXP1+, IRF4/MUM1+, cyK+, CD138+), while germinal center markers (Bcl-6, CD10, TCL1, GCET1) and immature B-cell markers (TdT) were negative. Cyclin D1 was included to exclude the remote possibility of a blastoid variant of mantle cell lymphoma, and also because plasma cell myeloma can be cyclin D1-positive. Hairy cell leukemia markers (Annexin A1, DBA44, TRAP) were investigated to exclude the very remote possibility of evolution from hairy cell leukemia (in consideration of the clinical setting).

Cell Cycle {#s3c}
----------

DNA content of VR09 cell line was analyzed at six months and one year of culture. High S-phase rate was observed (diploid S 22.66%), in absence of tetraploid or aneuploid peak, as compared to the control (diploid S: 1.64%).

IVGH, TP53, CARD11, CD79B and MYD88 Mutation Analysis {#s3d}
-----------------------------------------------------

VR09 cell line and the DNA from the patient showed the same VH3-7/D4-23/JH4 gene rearrangement. The comparison of the sequence with published germline sequences showed 95.7% identity in both VR09 cell line and DNA from the patient, with evidence of somatic hypermutation (SHM) in the VH region, defined as more than 2% mutations as compared to germline sequences. The analysis of the sequences obtained from both strands of cDNA and compared with the published *TP53* sequence (U94788.1) showed that this sequence in VR09 cell line was wild-type *(data not shown)*. *CARD11* sequence was compared to the published one (NM_032415): VR09 cell line showed a silent heterozygous mutation leading to D533D variation in the protein linker region. Finally, VR09 cell line expressed all the three isoforms of the CD79B gene (NM_000626.2; NM_021602.2; NM_001039933.1): cDNA sequence analysis showed that variants 1 and 3 had an homozygous silent mutation in exon 3 leading to C122C variation in the Ig-like V-type protein domain, involving the disulfide bond; moreover, variant 2 had an Alanine insertion in the exon 2b corresponding to the protein signal peptide region. The analysis of exons 1 to 5 of *MYD88* showed no mutations compared to the reference sequence (NG_016964).

Mouse Model {#s3e}
-----------

All six mice injected s.c. with VR09 cell line developed spherical tumor masses around the site of injection by 34--74 days after treatment and were sacrificed 10 days later. Subcutaneous mass and tumor incidence *in vivo* are shown in [**Figure 3**](#pone-0052811-g003){ref-type="fig"}. Cells from subcutaneous masses were evaluated by H&E and Giemsa staining: cells ranged from medium to large size, with irregular nuclei, condensed chromatin without nucleoli and basophilic cytoplasm. Immunohistochemistry showed no significant differences in tumor cell immunophenotype as compared to VR09 cell line in culture ([**Table 2**](#pone-0052811-t002){ref-type="table"} and [**Figure 4**](#pone-0052811-g004){ref-type="fig"}).

![Cell line growth in vivo. (\
A) Spherical subcutaneous mass (arrow) in Rag-2^−/−^ γ-chain^−/−^ mice 36 days after VR09 cell line injection (representative case). (B) Timing of tumor development *in vivo* (6 mice s.c. injected with 5×10^6^ cells/mouse).](pone.0052811.g003){#pone-0052811-g003}

![Representative histological markers detected on tumors.\
High magnification (20X) of histological sections of tumors developing after *in vivo* injection of VR09 cell line. Lymphoid infiltrates display large size, plasmablastic-plasmacytic features and high Ki-67 index. Cells express CD19, CD20, CD138, CD79a, IgM, IgG and EBV protein (EBER).](pone.0052811.g004){#pone-0052811-g004}

Cells suspensions obtained by disaggregation of *in vivo* tumor masses showed proliferative capacity when cultured with the same procedure used for primary VR09 cell line. Again, cells appeared as small and round clumps with plasmacytoid features and bizarre shape: immunophenotyping on these cells after two months of continuous secondary culture did not show any significant change of cell surface marker expression as compared to primary VR09 cell line ([**Figure 2**](#pone-0052811-g002){ref-type="fig"}).

Of the six i.v. injected mice, three were euthanized after 30 days from injection and the other 3 after four months: histopathologic examination of spleen, liver, femurs, lymph nodes and lungs did not show any evidence of tumor infiltration. In addition, no circulating human CD45/CD19-positive cells were detected in peripheral blood of both s.c. and i.v. injected mice.

EBV Status {#s3f}
----------

EBV RNA evaluation was performed on FFPE cell blocks and tumoral masses by using a fluorescein-conjugated probe coupled to chromogenic detection (Bond ISH EBER Probe, Vision-Biosystem, Menarini, Florence, Italy). In situ hybridization for EBV-encoded RNA (EBER) showed a clear nuclear signal in both VR09 cell line and tumors ([**Table 2**](#pone-0052811-t002){ref-type="table"} and [**Figure 4**](#pone-0052811-g004){ref-type="fig"}).

Analysis of the RPMS1 gene PCR products, performed on both DNA from patient and VR09 cell line, showed the same 151 bp specific amplicon ([**Figure 5**](#pone-0052811-g005){ref-type="fig"}), thus showing that EBV infection was already present at the beginning of culture.

![EBV positivity in the original tumor and in the VR09 cell line.\
PCR products analysis by Agilent 2100 Bioanalyzer showed the presence of the same 151 bp specific amplicon for EBV RPMS1 gene, thus demonstrating that EBV infection was present in the original cells from patient. A normal DNA from pancreas was used as negative control.](pone.0052811.g005){#pone-0052811-g005}

Karyotyping {#s3g}
-----------

Chromosome analysis performed at 10 weeks and one year of continuous culture showed a male karyotype with 47 chromosomes. All metaphases exhibited trisomy of chromosome 12. Karyotype was repeated on secondary cell cultures obtained by disaggregation of *in vivo* tumor masses, thus revealing the presence of additional structural chromosome aberration involving chromosomes 7 and 9, i.e. 47, XY, der(7)(9qter-\>9p23::7p13-\>7qter), +der(7)(9qter-\>9p23::7p13-\>7qter), −9, +12 ([**Figure 6A**](#pone-0052811-g006){ref-type="fig"}).

![Karyotyping and FISH of secondary culture.\
(A) Trisomy of chromosome 12 and structural chromosome aberration involving chromosomes 7 and 9 on secondary culture detected by karyotype; (B) Chromosome 9 staining by FISH of secondary culture.](pone.0052811.g006){#pone-0052811-g006}

Fluorescence in situ Hybridization (FISH) {#s3h}
-----------------------------------------

Adjacent or fused fluorescent signals (LSI BCL-2) were found in 5% of nuclei on tissue sections; this percentage is below the established 10% signal threshold for considering a case positive (adjacent signals are generated by random overlapping of genomic regions). No break-apart fluorescent signals were found for LSI CCND1 (11q13) and LSI MYC (8q) probes on tissue sections. No adjacent or fused fluorescent signals were found for LSI IGH/CCND and LSI C-MYC dual color probes (4% of nuclei, below threshold). Trisomy of chromosome 12 was found in 45% of nuclei. The rearrangement involving chromosomes 9 and 7 detected by karyotyping on cell suspension from *in vivo* tumor mass was confirmed by fluorescent signals derived from hybridization of chromosome 9 DNA probes to target chromosome 9 (chromosome 9 paint) ([**Figure 6B**](#pone-0052811-g006){ref-type="fig"}). The main features of VR09 cell line are summarized in [**Table 3**](#pone-0052811-t003){ref-type="table"}.

10.1371/journal.pone.0052811.t003

###### Summary of VR09 cell line features.

![](pone.0052811.t003){#pone-0052811-t003-3}

  Parameter                                                                               Features
  ------------------------------- -------------------------------------------------------------------------------------------------------------------------
  ***Cell Line***                 
  Name of cell line                                                                         VR09
  Cell line type                                                                          Lymphoid
  Cell phenotype                   CD19+ CD20+ CD79a+ CD79b+/− CD138+ cyclin D1- Ki67 80% IgM+ IgD+ MUM1+ MNDA+ CD10− CD22+ CD23+ CD43+ K+, λ− Bcl2+ Bcl6−
  Cytogenetic karyotype                                                           Trisomy of chromosome 12
  Mutation analysis                                                                    VH3-7/D4-23/JH4
  Tumorigenic capacity                                     Subcutaneously growth into immunodeficient Rag2^−/−^ γ-chain^−/−^ mice
  ***Clinical data***             
  Primary disease of patient                            Atypical B-cell chronic lymphoproliferative disease with plasmacytic features
  Disease Status                                                                        At diagnosis
  Patient data (age, race, sex)                                                   75-year old Caucasian man
  Source of material                                                                     Bone marrow
  Year of establishment                                                                     2008
  ***Cell culture data***         
  Culture Medium                                                                        RPMI 10% FBS
  Subcultivation routine                                       Maintained at 0.5--1×1.0^6^ cells/mL; 1∶5 split every 72 hours
  Minimum cell density                                                               0.5×10^6^ cells/mL
  Maximum cell density                                                               1.0×10^6^ cells/mL
  Doubling time                                                                           84 hours
  Cell storage condition                                         60% RPMI 1640 medium, 30% heat-inactivated FBS and 10% DMSO
  In situ morphology                    medium-to-large sized cells, plasmacytoid features and occasional bizarre shapes; round clumps in suspension
  Viral status                                                                          EBV-positive

Discussion {#s4}
==========

We describe here the establishment and molecular characterization of novel human EBV-positive DLBCL cell line with plasmacytic differentiation obtained from a patient with atypical B-cell chronic lymphoproliferative disease with plasmacytic features.

Human B-lymphoid cell lines are extensively used world wide as models in studies of various aspects of B cell biology and as a tools in research on the pathogenesis of leukemia and lymphoma. Nevertheless, the efficiency establishment of new leukemia and lymphoma cell line is rather low and remains a random process [@pone.0052811-Drexler1]. Sometimes, the spontaneous proliferation and immortalization of normal or malignant cells *in vitro* is due to EBV infection. It is well known for several decades that infection of normal B cell with EBV leads to establishment of lymphoblastoid cell line, thus confirming its oncogenic potential [@pone.0052811-Nilsson1]. EBV is associated to several malignancies *in vivo* and may lead to spontaneous growth and transformation of malignant cells *in vitro* [@pone.0052811-Altmann1]; nevertheless, lymphoproliferative cell lines from CLL-like chronic lymphoproliferative disorders have never been reported, unless infected by EBV or in prolymphocytoid transformation [@pone.0052811-Stacchini1]. The establishment of VR09 cell line was likely due to EBV infection; in fact, as EBV was already present in patient's B cells, we can reasonably assume that the infection drove the transformation into DLBCL once cultured *in vitro* and injected into mice, thus excluding a culture-dependent contamination by EBV. Indeed, the Association between EBV infection and indolent B-cell neoplasms, such as chronic lymphocytic leukemia, marginal zone lymphoma, lymphoplasmacytic lymphoma has been reported [@pone.0052811-Tarrand1], [@pone.0052811-Varghese1], [@pone.0052811-Kojima1] Thus, the positivity of EBV in VR09 cell line is not surprising. Moreover, some studies showed that cases of DLBCL developed from low-grade lymphoproliferative diseases are EBV-positive and that EBV may have a potential role, although not yet completed defined, in the progression of the indolent disease [@pone.0052811-Tsimberidou1], [@pone.0052811-Lin1].

Unfortunately, we lack much information about the patient; however, bone marrow cell morphology and immunophenotype are in agreement with the diagnosis of atypical, non-CLL B-cell chronic lymphoproliferative disease with plasmacytic features. Low-grade B-cell lymphoproliferative disorders, such as CLL/small lymphocytic lymphoma and marginal zone B-cell lymphoma may have overlapping features, thus making the differential diagnosis sometimes difficult. Furthermore, many types of small B lymphoid neoplasms can display plasmacytic differentiation and a phenotype resembling lymphoplasmacytic lymphoma; the latter consists of small lymphocytes, plasmacytoid lymphocytes and plasma cells expressing IgM and pan-B-cell antigens, such as CD19, CD20 and CD22, and usually negative for CD5, CD10 and CD23. As we lack information about serum IgM paraprotein, we concluded as a case of atypical B-chronic lymphoproliferative disease with plasmacytic differentiation, rather than a plasmacytic lymphoma.

Among lymphoproliferative disorders, VR09 cell line presents features of DLBCL with plasmacytic differentiation, with medium to large sized and plasmablastic/plasmacytic-like cells, high Ki-67 index and activated phenotype according to Hans' and new immunostaining algorithm [@pone.0052811-Choi1]. Moreover, cells are positive for MUM1, CD38, and CD138, thus suggesting a terminal-B cell differentiation.

Although lymphoplasmacytic lymphoma and other lymphoproliferative disease with plasmacytic differentiation may develop into diffuse large B cell lymphoma, similarly to CLL, the frequency of transformation is low [@pone.0052811-Lin1]. Consequently, VR09 cell line can be useful as a model of DLBCL variant corresponding to a very late or activated stage of B cell maturation [@pone.0052811-Falini1], i.e. the early post-germinal stage differentiation, not entirely terminally differentiated.

Despite the aggressive transformation of indolent disease is not always clonally related to original disease, some data are indirectly consistent with the hypothesis of clonal evolution: in fact, VR09 cell line maintains the immunophenotype and plasmacytoid features of the primary cells at diagnosis, displays the presence of the same clonal gene rearrangement found in patient's DNA and has a tumorigenic capacity *in vivo*; the latter feature strongly suggests its malignant behaviour. VR09 cell line grow subcutaneously without dissemination in peripheral blood and no engraftment when it is administrated i.v. This strange peculiarity could be simply due to the *in vivo* model used, i.e. Rag2^−/−^ γ-chain^−/−^ mice. They are immunodeficient mice with C57B16/10 background devoid of functional B and T cells because of the complete lack of function of the V(D)J recombinase enzyme system, and displaying deficient innate immunity due to the absence of γ chain of interleukin-2-receptor [@pone.0052811-Shinkai1]. This model has the advantage to show a stable phenotype without developing spontaneous tumors, as compared to SCID mice [@pone.0052811-VanRijn1]. Indeed, VR09 cell line injection led to 100% incidence of developing tumors *in vivo*, always maintaining the same features.

We found trisomy of chromosome 12 in our model. This aberration is often detected in chronic lymphocytic leukemia [@pone.0052811-Stilgenbauer1], [@pone.0052811-Hjalmar1] and in other chronic B cell malignancies, including sometimes lymphoplasmacytic lymphoma. We also found an additional chromosomal abnormality involving chromosomes 7 and 9 after secondary culture: genetic alterations of cell lines are usually stable over the time, but it is debated whether cell line may acquire additional rearrangements in culture [@pone.0052811-Drexler1].

We also found a synonymous variant of CD79B involving the insertion of Alanine in the exon 2b of variant 2. This variant may be physiological since it has been detected in other isoforms; however, it has never been described before. Moreover, a recent study suggested that also synonymous variants may be involved in the pathogenesis of some diseases [@pone.0052811-Brest1]; therefore, one could speculate that this novel variant of CD79B gene could be involved in the pathogenesis of lymphomas. VR09 cell line did not display the common missense mutations of Card11, usually involved in the constitutive activation of NF-kB pathway in some cases of human activated-B-cell like DLBCL [@pone.0052811-Lenz1]. However, the detection of synonymous mutations of Card11 reveals the accuracy of sequencing method. Interestingly, VR09 cell line showed unmutated Myd88 gene, differently from what described in recents reports [@pone.0052811-Puente1], [@pone.0052811-Ngo1], thus suggesting that lymphomas with plasmacytic features may have different gene patterns.

In conclusion, VR09 is a new cell line of activated DLBCL with plasmacytic differentiation that grow as solitary tumor once injected s.c. in immunodeficient mice. This model could be useful for further studies about the development of DLBCL in patients with low-grade B-cell lymphoproliferative disorders with plasmacytic differentiation, which is a rare but possible event in clinical practice.
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